Skip to content

Incidence of increased Pain After Supra-clavicular Nerve Block Wears Off, With and Without Adding Dexmedetomidine

INCIDENCE OF REBOUND PAIN WITH OR WITHOUT DEXMEDETOMIDINE AS AN ADJUVANT IN SUPRA-CLAVICULAR BLOCK - A RANDOMISED CONTROL TRIAL - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092386
Enrollment
32
Registered
2025-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Group A: Under USG Guidance, Supraclavicular Block given using Drug volume of total 30cc which contains mixture of Bupivacaine 0.5% 15cc, Lignocaine with Adrenaline 2% 10cc, Dexmedetomi

Sponsors

Vinayaka mission medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Scheduled for elective surgeries (upper limb, upper thorax) requiring supra-clavicular block. ASA physical status classification I or II. Willingness to participate and provide informed consent.

Exclusion criteria

Exclusion criteria: Contraindications to supra-clavicular block. Allergy or intolerance to dexmedetomidine or local anesthetics. History of chronic pain syndromes or opioid dependence. Pregnant or breast feeding women. Significant co-morbidities. Inability to communicate effectively or understand study instructions.

Design outcomes

Primary

MeasureTime frame
To determine whether the addition of dexmedetomidine to the local anesthetic solution used in supra-clavicular block reduces the incidence of rebound pain in patients undergoing upper limb surgeries compared to those receiving local anesthetics alone.Timepoint: first 24 hours from the time of drug injection

Secondary

MeasureTime frame
Compare rebound pain in dexmedetomidine vs. control. Analyse opioid use post-surgery with/without dexmedetomidine. Assess block onset/duration with dexmedetomidine. Investigate adverse effects of dexmedetomidine.Timepoint: Every 10 mins from block given and first 24 hours from the time of drug injection

Countries

India

Contacts

Public ContactDr Rahul Kumar

Vinayaka mission medical college and hospital

rkroy5577@gmail.com9955555120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026